Details for Patent: 10,555,902

Which drugs does patent 10,555,902 protect, and when does it expire?

Patent 10,555,902 protects TASCENSO ODT and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 10,555,902

Title:	Stable fingolimod dosage forms
Abstract:	The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
Inventor(s):	Liu; Fangyu (Saratoga, CA)
Assignee:	Handa Pharmaceuticals LLC (San Jose, CA)
Application Number:	15/918,582
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,555,902

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cycle	TASCENSO ODT	fingolimod lauryl sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	214962-001	Dec 23, 2021		RX	Yes	No						TREATMENT OF MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER AND WEIGHING LESS THAN OR EQUAL TO 40 KG
Cycle	TASCENSO ODT	fingolimod lauryl sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	214962-002	Dec 9, 2022		RX	Yes	Yes						THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS) IN PATIENTS 10 YEARS OF AGE AND OLDER

International Family Members for US Patent 10,555,902

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016209466
Canada	2974375
China	107530301
European Patent Office	3247341
Japan	2018502168
Taiwan	201642842